EP1019427A4 - N6-substituierte adenosin-5'-uronamide als adenosin-rezeptor-modulatoren - Google Patents

N6-substituierte adenosin-5'-uronamide als adenosin-rezeptor-modulatoren

Info

Publication number
EP1019427A4
EP1019427A4 EP98939156A EP98939156A EP1019427A4 EP 1019427 A4 EP1019427 A4 EP 1019427A4 EP 98939156 A EP98939156 A EP 98939156A EP 98939156 A EP98939156 A EP 98939156A EP 1019427 A4 EP1019427 A4 EP 1019427A4
Authority
EP
European Patent Office
Prior art keywords
adenosine
uronamides
substituted
receptor modulators
adenosine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98939156A
Other languages
English (en)
French (fr)
Other versions
EP1019427A1 (de
Inventor
Pier G Baraldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedCo Research Inc
Original Assignee
MedCo Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedCo Research Inc filed Critical MedCo Research Inc
Publication of EP1019427A4 publication Critical patent/EP1019427A4/de
Publication of EP1019427A1 publication Critical patent/EP1019427A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EP98939156A 1997-07-29 1998-07-29 N6-substituierte adenosin-5'-uronamide als adenosin-rezeptor-modulatoren Withdrawn EP1019427A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5406497P 1997-07-29 1997-07-29
US54064P 1997-07-29
PCT/US1998/016053 WO1999006053A1 (en) 1997-07-29 1998-07-29 N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators

Publications (2)

Publication Number Publication Date
EP1019427A4 true EP1019427A4 (de) 2000-07-19
EP1019427A1 EP1019427A1 (de) 2000-07-19

Family

ID=21988552

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98939156A Withdrawn EP1019427A1 (de) 1997-07-29 1998-07-29 N6-substituierte adenosin-5'-uronamide als adenosin-rezeptor-modulatoren

Country Status (5)

Country Link
EP (1) EP1019427A1 (de)
JP (1) JP2003517423A (de)
AU (1) AU8764398A (de)
CA (1) CA2296485A1 (de)
WO (1) WO1999006053A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0991414A4 (de) * 1997-05-09 2002-10-02 Univ Pennsylvania Methoden und zusammensetzungen zur reduktion ischaemischer schaeden am herzen durch gabe von adenosinrezeptoragonisten und -antagonisten
MXPA00011889A (es) 1998-06-02 2003-04-25 Osi Pharm Inc Composiciones de pirrolo (2,3d) piridina y su uso.
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DK1246623T3 (da) 1999-12-02 2006-11-13 Osi Pharm Inc Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2002035231A1 (en) * 2000-10-26 2002-05-02 Actar Ab Screening method using a g coupled receptor associated with a specific g protein
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
ATE292973T1 (de) 2001-01-16 2005-04-15 Can Fite Biopharma Ltd Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
EP1450811B1 (de) 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
CN1620294A (zh) 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
CN1816551A (zh) 2001-12-20 2006-08-09 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7368438B2 (en) 2003-10-21 2008-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
WO2006011130A1 (en) * 2004-07-28 2006-02-02 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren’s syndrome
EP1798233A1 (de) * 2005-12-19 2007-06-20 Faust Pharmaceuticals Pyrrolo[1,2-a]chinoxalinderivate als Adenosin-A3-Receptorenmodulatore und deren Verwendung
CN101820883B (zh) 2007-10-15 2013-03-20 坎-菲特生物药物有限公司 A3ar激动剂在用于制备刺激肝细胞增殖的药物中的应用
JP5849044B2 (ja) 2009-05-17 2016-01-27 キャン−ファイト バイオファーマ リミテッド 眼圧低下のためのａ３アデノシン受容体作動薬
EP2456419B1 (de) 2009-07-21 2016-11-23 Oradin Pharmaceutical Ltd. A3 adenosine rezeptor liganden zur modulation der pigmentierung
MX2012010006A (es) 2010-03-03 2013-01-17 Us Gov Health & Human Serv Agonistas de a3ar para el tratamiento de uveitis.
US9549943B2 (en) 2012-08-09 2017-01-24 Can-Fite Biopharma Ltd. A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina Adenosine a3 receptor ligand for use in lowering adipocyte levels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050047A1 (en) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050047A1 (en) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C.GALLO-RODRIGUEZ ET AL.: "Structure Activity Relationships of N6-Benzyladenosine-5'-uronamides as A3 Selective Adenosine Agonists.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 37, no. 5, 4 March 1994 (1994-03-04), AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 636 - 646, XP002136400, ISSN: 0022-2623 *
H.O.KIM ET AL.: "2-Substitution of N6-Benzoyladenosine-5'-Uronamides Enhances Selectivity for A3 Adenosine Receptors.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 37, no. 21, 14 October 1994 (1994-10-14), AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 3614 - 3621, XP002136401, ISSN: 0022-2623 *
See also references of WO9906053A1 *

Also Published As

Publication number Publication date
CA2296485A1 (en) 1999-02-11
JP2003517423A (ja) 2003-05-27
EP1019427A1 (de) 2000-07-19
WO1999006053A1 (en) 1999-02-11
AU8764398A (en) 1999-02-22

Similar Documents

Publication Publication Date Title
EP1019427A4 (de) N6-substituierte adenosin-5'-uronamide als adenosin-rezeptor-modulatoren
GB2353527B (en) Adenosine A3 receptor modulators
GB9715751D0 (en) Formulations
HUP0100536A3 (en) Fiber distributor
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
EP0996458A4 (de) Sandramycin analoge
IL133920A0 (en) Trail receptor
AU7132898A (en) Edg-1-like receptor
GB9517098D0 (en) Receptor
GB9617923D0 (en) Novel receptor
EP0973800A4 (de) Neuartiger rezeptor
GB2321753B (en) Metering system
GB9701050D0 (en) Structural member
PL340723A1 (en) Structural member
GB9515669D0 (en) Releasable fixing means
GB9425502D0 (en) Novel receptor
ZA987267B (en) Nucleosides
IL139493A0 (en) Adenosine a3 receptor modulators
IL156851A0 (en) Adenosine a3 receptor modulators
GB9703676D0 (en) Stable system
GB9710434D0 (en) Distributor units
HU0002453D0 (en) Novel nucleosides
CA81596S (en) Structural member
AU133746S (en) Distributor
AUPO910797A0 (en) Receptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000202

A4 Supplementary search report drawn up and despatched

Effective date: 20000606

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010330

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011010